Tissue factor pathway inhibitor in atherosclerosis.
Review published in Clinica chimica acta; international journal of clinical chemistry (2019)
Abstract
Tissue factor pathway inhibitor (TFPI) reduces the development of atherosclerosis by regulating tissue factor (TF) mediated coagulation pathway. In this review, we focus on recent findings on the inhibitory effects of TFPI on endothelial cell activation, vascular smooth muscle cell (VSMC) proliferation and migration, inflammatory cell recruitment and extracellular matrix which are associated with the development of atherosclerosis. Meanwhile, we are also concerned about the impact of TFPI levels and genetic polymorphisms on clinical atherogenesis. This article aims to explain the mechanism in inhibiting the development of atherosclerosis and clinical effects of TFPI, and provide new ideas for the clinical researches and mechanism studies of atherothrombosis.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Tissue factor pathway inhibitor (TFPI) reduces the development of atherosclerosis by regulating tissue factor (TF) mediated coagulation pathway. In this review, we focus on recent findings on the inhibitory effects of TFPI on endothelial cell activation, vascular smooth muscle cell (VSMC)...
Warum dies für die Hirudotherapie relevant ist
This review examined the role of tissue factor pathway inhibitor (TFPI) in reducing atherosclerosis by regulating coagulation pathways, endothelial cell activation, vascular smooth muscle cell proliferation and migration, and inflammatory cell recruitment. The abstract discusses only the endogenous inhibitor TFPI and its impact on atherogenesis, including genetic polymorphisms and clinical effects. For the American Society of Hirudotherapy, the topic of coagulation inhibition is conceptually adjacent, but the abstract contains no mention of leeches, hirudotherapy, leech-derived compounds, or the leech secretome. Any relevance is purely indirect, as the review does not evaluate or compare exogenous anticoagulants from any source.
Zitation
Tissue factor pathway inhibitor in atherosclerosis.
Yuan et al. · Clinica chimica acta; international journal of clinical chemistry, 2019
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026